172 related articles for article (PubMed ID: 31314616)
1. Modeling the potential impact of abuse-deterrent opioids on medical resource utilization.
Yenikomshian MA; White AG; Carson ME; Jia ZB; Mendoza MR; Roland CL
J Med Econ; 2019 Oct; 22(10):1073-1079. PubMed ID: 31314616
[No Abstract] [Full Text] [Related]
2. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
3. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
4. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
[TBL] [Abstract][Full Text] [Related]
5. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
[TBL] [Abstract][Full Text] [Related]
6. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.
White AG; Birnbaum HG; Rothman DB; Katz N
Appl Health Econ Health Policy; 2009; 7(1):61-70. PubMed ID: 19558195
[TBL] [Abstract][Full Text] [Related]
7. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
8. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
Rauck RL
Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
[TBL] [Abstract][Full Text] [Related]
9. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
10. Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.
White AG; LeCates J; Birnbaum HG; Cheng W; Roland CL; Mardekian J
J Opioid Manag; 2015; 11(3):199-210. PubMed ID: 25985805
[TBL] [Abstract][Full Text] [Related]
11. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
Fanelli A; Sorella MC; Ghisi D
Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
[TBL] [Abstract][Full Text] [Related]
12. Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets.
Webster LR; Viscusi ER; Brown C; Dayno JM
Curr Med Res Opin; 2018 May; 34(5):893-901. PubMed ID: 29368961
[TBL] [Abstract][Full Text] [Related]
13. An evaluation method for developing abuse-deterrent opioid formulations with agonist and antagonist combinations using conditioned place preference.
Zhang X; Kitaichi K; Mouri A; Zhou X; Nabeshima T; Yamada K; Nagai T
Biochem Biophys Res Commun; 2023 Jan; 639():100-105. PubMed ID: 36476949
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.
Vadivelu N; Schermer E; Kodumudi G; Berger JM
CNS Drugs; 2016 Jul; 30(7):637-46. PubMed ID: 27290716
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
16. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
17. Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective.
Gadd S; Cox N; Samuelson J; Kenney A; Turner K; Cochran G
Ther Drug Monit; 2021 Feb; 43(1):35-41. PubMed ID: 33278243
[TBL] [Abstract][Full Text] [Related]
18. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
Webster LR; Markman J; Cone EJ; Niebler G
Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
[TBL] [Abstract][Full Text] [Related]
19. Abuse-deterrent opioid analgesics: a guide for clinicians.
Carinci AJ
Pain Manag; 2020 Jan; 10(1):55-62. PubMed ID: 31916895
[TBL] [Abstract][Full Text] [Related]
20. Abuse-deterrent opioids: an update on current approaches and considerations.
Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
